Prolonged complete response to adjuvant tepotinib in a patient with newly diagnosed disseminated glioblastoma harboring mesenchymal-epithelial transition fusion

• Published in: The oncologist (Dayton, Ohio) Vol. 30; no. 1
• Main Authors: Pham, Lily C, Weller, Lauryn, Gann, Claudia N, Schumacher, Karl Maria, Vlassak, Soetkin, Swanson, Todd, Highsmith, Kaitlin, O’Brien, Barbara J, Nash, Sebnem, Aaroe, Ashley, de Groot, John F, Majd, Nazanin K
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 01.01.2025
• Subjects: Adjuvants; Blood-brain barrier; Brain Neoplasms - drug therapy; Brain Neoplasms - genetics; Brain Neoplasms - pathology; Cancer therapies; Clinical outcomes; Clinical trials; Drug dosages; Drug therapy; Epithelial cells; Glioblastoma - drug therapy; Glioblastoma - genetics; Glioblastoma - pathology; Glioblastoma multiforme; Glioma; Growth factors; Health aspects; Humans; Kinases; Medical diagnosis; Medical prognosis; Mutation; Neutropenia; Oncology; Patients; Pharmacology, Experimental; Phosphorylation; Physiological aspects; Piperidines - administration & dosage; Piperidines - therapeutic use; Proto-Oncogene Proteins c-met - antagonists & inhibitors; Proto-Oncogene Proteins c-met - genetics; Pyridazines - administration & dosage; Pyridazines - therapeutic use; Pyrimidines - administration & dosage; Pyrimidines - therapeutic use; Radiation; Stem cells; Targeted cancer therapy; Tumors; United States; molecular alteration; targeted therapy; tepotinib; glioblastoma; outcomes

Abstract The prognosis of patients with glioblastoma (GBM) remains poor despite current treatments. Targeted therapy in GBM has been the subject of intense investigation but has not been successful in clinical trials. The reasons for the failure of targeted therapy in GBM are multifold and include a...